Methylated Tissue Factor Pathway Inhibitor 2 (TFPI2) DNA in Serum Is a Biomarker of Metastatic Melanoma
- 1 May 2013
- journal article
- research article
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 133 (5) , 1278-1285
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- A Multicenter Prospective Evaluation of the Clinical Utility of F-18 FDG-PET/CT in Patients With AJCC Stage IIIB or IIIC Extremity MelanomaAnnals of Surgery, 2012
- Improved Survival with MEK Inhibition in BRAF-Mutated MelanomaNew England Journal of Medicine, 2012
- Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical useJournal of Translational Medicine, 2012
- Targeting Metastatic MelanomaAnnual Review of Medicine, 2012
- CD24 promotes tumor cell invasion by suppressing tissue factor pathway inhibitor-2 (TFPI-2) in a c-Src-dependent fashionClinical & Experimental Metastasis, 2011
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- Knockdown of TFPI-2 promotes migration and invasion of glioma cellsNeuroscience Letters, 2011
- Next generation therapies change the landscape in melanomaF1000 Medicine Reports, 2011
- Melanoma biology and new targeted therapyNature, 2007
- The genetics of malignant melanoma: lessons from mouse and manNature Reviews Cancer, 2003